Hormonal Dimorphism In Sarcopenia Disease
As we age, many of us experience a natural decline in muscle mass and strength, a condition called sarcopenia. This can make everyday activities challenging and impact our overall health. For a long time, treatments for sarcopenia have largely followed a “one-size-fits-all” approach. However, new research highlights a crucial difference: sarcopenia doesn’t affect men and women in the same way, especially when it comes to hormones.
The latest findings reveal that the hormonal changes driving muscle loss are distinct for each sex. In women, a rapid drop in estrogen during menopause significantly contributes to muscle decline. This hormonal shift can disrupt important signals in the body, like those involving a peptide called apelin, which is involved in cell communication, and can also lead to increased insulin resistance, where the body struggles to use insulin effectively to manage blood sugar. Additionally, it can impair the regenerative processes linked to oxytocin, a hormone known for its role in social bonding but also important for muscle repair.
In contrast, men typically experience a more gradual reduction in testosterone, which also plays a vital role in maintaining muscle. These sex-specific hormonal changes mean that the underlying mechanisms of sarcopenia are different. For example, apelin appears to be a more relevant indicator of muscle health in women, while another protein called myostatin, which limits muscle growth, is more specific to men.
Understanding these “hormonal dimorphisms” – or sex-specific differences in hormone effects – is critical. It suggests that current treatments might be more effective for one sex than the other. Moving forward, developing personalized strategies that consider these distinct biological pathways could lead to much more effective ways to prevent and treat age-related muscle loss for everyone.
Source: link to paper